The burden of alcohol-associated liver disease (ALD) in the United States has increased precipitously, 1,2 paralleling the increasing prevalence of high-risk alcohol use and alcohol use disorder (AUD). 3 Between the years 2001 and 2012, the prevalence of AUD increased by 50% in the United States, with an astonishing 84% increase in women. Patients with ALD are initially seen at more advanced stages than other liver diseases, contributing to its disproportionate health care utilization and costs. 1,4 Furthermore, ALD is now the most common indication for liver transplantation in the United States. 5 This burden is likely to increase significantly in the wake of the coronavirus disease 2019 (COVID-19) pandemic. 6 The only proven and durable therapy for ALD is abstinence from alcohol, which requires screening for and treatment of comorbid unhealthy alcohol use and AUD through behavioral interventions and/or pharmacotherapy. Unfortunately, less than 10% of individuals with AUD living in the United States receive any treatment within 12 months of diagnosis. 7 Treatment of coexisting AUD in patients with cirrhosis has been shown to reduce mortality and interval decompensation. 8 Effective treatment of AUD and ALD often requires a multidisciplinary approach, 9 involving specialists in addiction, psychiatry, gastroenterology, hepatology, and social work, which is not available in all practice settings. In a survey-based study of providers Abbreviations: AASLD, American Association for the Study of Liver Diseases; ALD, alcohol-associated liver disease; ASAM,